NPM1 and hematopoietic and lymphoid system neoplasm: Acute myeloid leukemia (AML) with nucleophosmin (NPM1) mutation was fully accepted as a specific AML category in the 2017 World Health Organization (WHO) classification of hematologic neoplasms, with the requirement of a blast cell count ≥ 20% for its diagnosis.